{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.17","upperLimit":"13.34","value":"11.1"},{"comment":"Unable to Estimate due to low numbers.","groupId":"OG001","lowerLimit":"7.92","upperLimit":"NA","value":"8.0"},{"groupId":"OG002","lowerLimit":"5.88","upperLimit":"11.73","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.","id":"OG000","title":"NRE Cohort - CRPC 100 mg"},{"description":"cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.","id":"OG001","title":"NRE Cohort - CRPC 39.4 mg"},{"description":"cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.","id":"OG002","title":"NRE Cohort - Ovarian 100 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 15 months","title":"Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only","type":"SECONDARY","unitOfMeasure":"months"}